Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | TYR | P14679 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6386316 | 0.90 | BCHE (0.50) | CA12CA1CA2CA7CA9 | |
| SCHEMBL3140878 | 0.90 | CA1 (0.43) | CA12CA1CA2CA7CA9 | |
| SCHEMBL4010343 | 0.90 | CA12 (0.43) | CA12CA1CA2CA7CA9 | |
| SCHEMBL414370 | 0.90 | MEN1 (0.48) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2632344 | 0.89 | BCHE (0.46) | CA12CA1CA2CA7CA9 | |
| SCHEMBL11399910 | 0.89 | CA12 (0.56) | CA12CA1CA2CA7CA9 | |
| SCHEMBL7691614 | 0.88 | MAPK1 (0.47) | ALDH1A1CYP3A4CYP2D6ADRA2AADRA1A | |
| SCHEMBL16437139 | 0.88 | CA12 (0.41) | CA12CA1CA2CA7CA9 | |
| SCHEMBL17189617 | 0.85 | HTR2A (0.42) | CA12CA1CA2CA7CA9 | |
| SCHEMBL16351174 | 0.85 | SLC2A1 (0.46) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2000004004-A1 | METHODS OF SYNTHESIZING SULTAMS AND ANTI-VIRAL COMPOSITIONS | THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION (US) | 2000-01-27 | — | — | WO | claimed |
| US-20250084012-A1 | METHOD FOR REMOVING TERT-BUTOXYCARBONYL GROUP | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-03-13 | — | — | US | disclosed |
| EP-4461715-A1 | METHOD FOR REMOVING TERT-BUTOXYCARBONYL GROUPS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-11-13 | — | — | EP | disclosed |
| US-9598714-B2 | Side-chain protected oligopeptide fragment condensation using subtilisins in organic solvents | ENZYPEP B.V. (NL) | 2017-03-21 | — | — | US | disclosed |
| US-20150037840-A1 | SIDE-CHAIN PROTECTED OLIGOPEPTIDE FRAGMENT CONDENSATION USING SUBTILISINS IN ORGANIC SOLVENTS | ENZYPEP B.V. (NL) | 2015-02-05 | — | — | US | disclosed |
| EP-2591795-A1 | RNA targeting compounds and methods for making and using same | The Research Foundation Of State University Of New York (US) | 2013-05-15 | — | — | EP | disclosed |
| EP-1713493-A4 | PITUITARY ADENYLATE CYCLASE ACTIVATING PEPTIDE (PACAP) RECEPTOR (VPAC2) AGONISTS AND THEIR PHARMACOLOGICAL METHODS OF USE | BAYER PHARMACEUTICALS CORP (US) | 2009-06-24 | — | — | EP | disclosed |
| US-20090143283-A1 | Pituitary Adenylate Cyclase Activating Peptide (PACAP) Receptor (VPAC2) Agonists and Their Pharmacological Methods of Use | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-06-04 | — | — | US | disclosed |
| US-20080221303-A1 | Method for the Preparation of Peptide-Oligonucleotide Conjugates | FRUTAROM LTD. (IL) | 2008-09-11 | — | — | US | disclosed |
| EP-1725250-A2 | METHOD FOR THE PREPARATION OF PEPTIDE-OLIGONUCLEOTIDE CONJUGATES | FRUTAROM LTD. (IL) | 2006-11-29 | — | — | EP | disclosed |
| EP-1713493-A2 | PITUITARY ADENYLATE CYCLASE ACTIVATING PEPTIDE (PACAP) RECEPTOR (VPAC2) AGONISTS AND THEIR PHARMACOLOGICAL METHODS OF USE | Bayer Pharmaceuticals Corporation (US) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005076744-A2 | METHOD FOR THE PREPARATION OF PEPTIDE-OLIGONUCLEOTIDE CONJUGATES | FRUTAROM LTD. (IL) | 2005-08-25 | — | — | WO | disclosed |
| WO-2005072385-A2 | PITUITARY ADENYLATE CYCLASE ACTIVATING PEPTIDE (PACAP) RECEPTOR (VPAC2) AGONISTS AND THEIR PHARMACOLOGICAL METHODS OF USE | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250084012-A1 | METHOD FOR REMOVING TERT-BUTOXYCARBONYL GROUP | TERT, MGMT, MITF | CA12 1377/4885CA1 2060/4885CA2 1471/4885 |
| US-20080221303-A1 | Method for the Preparation of Peptide-Oligonucleotide Conjugates | VIP, PTMS, SSTR4 | CA12 758/4885CA1 1256/4885CA2 4167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.